Marina Montagnani Marelli

TL;DR: The data seem to indicate that an autocrine/paracrine L HRH (or LHRH-like) loop is present in androgen-independent prostate cancer cells, and may participate in the regulation of tumor cell growth.

TL;DR: Increasing knowledge about the regulation of GnRH pulsatile release, as well as the therapeutic use of its analogues, offers interesting new perspectives in the diagnosis, treatment and outcome of female reproductive disorders, including tumoral and iatrogenic diseases.

TL;DR: Observations point to GnRH-I as an autocrine negative regulatory factor on tumor growth progression and metastatization, and the molecular mechanisms underlying the peculiar antitumor activity of Gn RH-I are clarified.

TL;DR: The present experiments demonstrate that the LHRH receptor, which is present in prostate cancer cells, independently of whether they are androgen-dependent or not, corresponds to the pituitary receptor, in terms of messenger RNA expression and protein molecular size.

TL;DR: Tumor GnRH-R are now considered a very interesting candidate for novel molecular, GnRH analog-based, targeted strategies for the treatment of tumors expressing these receptors.